|
Wolfram Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Circulating PSP/reg levels are also increased in some patients with Wolfram syndrome.
|
30914711 |
2019 |
|
Vertical supranuclear gaze palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Differentiating clinically progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) may be challenging, especially in the absence of vertical supranuclear gaze palsy (VSGP).
|
30068492 |
2018 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes.
|
28500751 |
2017 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease.
|
24086739 |
2013 |
|
Tauopathies
|
0.050 |
GeneticVariation
|
group |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
|
Suntan
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure.
|
29739929 |
2018 |
|
Substance-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance Use Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance Dependence
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance abuse problem
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
ST segment elevation myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Optimal BRS implantation, as assessed by PSP score, was associated with better post-procedural QCA parameters in STEMI.
|
30398966 |
2019 |
|
Spontaneous pneumothorax
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively reviewed and stratified 938 instances of pneumothorax in 751 consecutive patients diagnosed with SP into the PSP and SSP groups.
|
28386166 |
2017 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The combination of PSP@MB and the use of ultrasound can efficiently enhance accumulation, extravasation and penetration into solid tumors.
|
31814720 |
2019 |
|
soft neurological signs
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Patients with an established condition of TRS or ARS were assessed for: clinical presentation and course; neurological soft signs (NES); psychopathology by PANSS; cognitive performances; quality of life scale (QLS); functional capacity; social functioning (PSP and SLOF scales).
|
30195742 |
2018 |
|
soft neurological signs
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Psychotic symptoms by PANSS, social functioning by PSP and SLOF, clinical severity of the illness, cognitive functioning, and neurological soft signs (NSS) were assessed.
|
29934250 |
2018 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33).
|
30161055 |
2018 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Animal models suggest that early markers of Sjögren syndrome (EMS)-antibodies against salivary protein 1, parotid secretory protein, and carbonic anhydrase 6 (CA6)-are more accurate signals of early Sjögren when compared with classic markers (anti-Ro and anti-La).
|
31634227 |
2020 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Recently, the presence of novel tissue specific autoantibodies (TSAs), SP-1, CA6, and PSP, has been observed in the early stages of SS.
|
30572137 |
2019 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
In the Penn SICCA cohort, SP-1 IgM and PSP IgA autoantibodies were more prevalent in the serum of SS-related dry eye participants compared with those without SS.
|
31517725 |
2019 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Antibodies to SP-1, CA6 and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La.
|
23123440 |
2012 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
To investigate the value of 3 novel autoantibodies [salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP)] in differentiating Sjögren's syndrome (SS)-related dry eye from non-SS dry eye.
|
29504954 |
2018 |
|
Sjogren's Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Several newly-identified biomarkers for SS include autoantibodies to proteins specific to the salivary and lacrimal glands [SP-1 (salivary gland protein-1), PSP (parotid secretory protein), CA-6 (carbonic anhydrase VI)].
|
28283891 |
2017 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> To assess the prognostic value for 28-day mortality of PSP in critically ill patients with sepsis.
|
31621373 |
2019 |